论文部分内容阅读
正进行一些治疗心源性休克的双盲试验研究的研究者们,报道了其中一种研究的一些初步结果。在试验中的这种药物疗法是由R.H.Dietzman博士、R.Lilleheri博士以及明尼苏达大学外科系的合作者提出的。此项研究正在由四所学院完成。明尼苏达研究者们的工作起点是认为休克系组织灌流的病变。他们的实验和早期临床结果表明,可使组织灌流大大改善并提高了生存率(达60％),其治疗方法为:补充血容量(用代血浆或葡聚糖),采用加强心肌收缩力的药物(如洋地黄、异丙肾上腺素或去甲肾上腺素)
Some of the preliminary results of one of these studies are being reported by some researchers who are conducting double-blind trials of cardiogenic shock. The drug therapy in trials was presented by Dr. R.H. Dietzman, Dr. R. Lilleheri and collaborators at the University of Minnesota Department of Surgery. The study is being completed by four colleges. The Minnesota researchers started out as thinking about tissue-perfused lesions in shock. Their experiments and early clinical results show that the tissue perfusion can be greatly improved and the survival rate (up to 60%) can be greatly improved by treating the blood volume (using blood plasma or dextran), increasing the myocardial contractility Drugs (such as digitalis, isoproterenol or norepinephrine)